Company intelligence / Profile preview

Oncology Systems

Scottsdale, Arizona, United Statesoncologysystems.com ↗

Ownership: Private
Development stage: Commercial

Overview

Systems Oncology leverages AI and its proprietary Arromer multimodal RNA platform to develop next-generation cancer therapies. The company focuses on simultaneously silencing multiple disease targets with a single RNA molecule to address complex cancer pathways and drug resistance. Its programs are in preclinical development. No clinical results have been published.

Therapeutic areas: Oncology
Modalities: RNA therapyMultimodal RNA therapeutics
Industry: Biotech

Partnerships

Collaborations with leading universities for research and target validation

Beyond the preview

Go deeper on Oncology Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncology Systems.

Explore the full profile